within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX16_Deutetrabenazine;

model Deutetrabenazine
  extends Pharmacolibrary.Drugs.ATC.N.N07XX16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07XX16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor used primarily in the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. It is an approved drug, marketed under the brand name Austedo.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration of deutetrabenazine tablets.</p><h4>References</h4><ol><li><p>Heo, YA, &amp; Scott, LJ (2017). Deutetrabenazine: A Review in Chorea Associated with Huntington&#x27;s Disease. <i>Drugs</i> 77(17) 1857–1864. DOI:<a href=\"https://doi.org/10.1007/s40265-017-0831-0\">10.1007/s40265-017-0831-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29080203/\">https://pubmed.ncbi.nlm.nih.gov/29080203</a></p></li><li><p>Schneider, F, et al., &amp; Rabinovich-Guilatt, L (2022). The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers. <i>European journal of clinical pharmacology</i> 78(1) 11–18. DOI:<a href=\"https://doi.org/10.1007/s00228-021-03202-0\">10.1007/s00228-021-03202-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34491372/\">https://pubmed.ncbi.nlm.nih.gov/34491372</a></p></li><li><p>Schneider, F, et al., &amp; Rabinovich-Guilatt, L (2020). Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers. <i>Clinical and translational science</i> 13(4) 707–717. DOI:<a href=\"https://doi.org/10.1111/cts.12754\">10.1111/cts.12754</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32155315/\">https://pubmed.ncbi.nlm.nih.gov/32155315</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Deutetrabenazine;
